Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report
Jane M. Knisely, Lucas E. Buyon, Rebecca Mandt, R. Farkas, Shobana Balasingam, Karin Bok, Ursula J. Buchholz, M. Patricia D’Souza, Jennifer L. Gordon, Deborah King, Tung Thanh Le, Wolfgang W. Leitner, Robert A. Seder, Alkis Togias, Stig Tollefsen, David W. Vaughn, Daniel Wolfe, Kimberly L. Taylor, Anthony S. Fauci
Abstract
On November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic Preparedness Innovation (CEPI), The Bill & Melinda Gates Foundation (BMGF), The Biomedical Advanced Research and Development Authority (BARDA), and the Wellcome Trust hosted a virtual workshop entitled “Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities.” During the workshop, researchers and vaccine developers from around the world discussed the potential of mucosal vaccines to block SARS-CoV-2 transmission and reviewed the status of SARS-CoV-2 mucosal vaccine research. Here, we summarize key challenges and opportunities in basic, translational, and clinical research that were highlighted during the meeting. We also provide recommendations to advance the field and accelerate the development of mucosal vaccines for SARS-CoV-2.